USD 4.70 billion
Report ID:
SQMIG35A2786 |
Region:
Global |
Published Date: July, 1990
Pages:
219
|Tables:
93
|Figures:
70
Biologics Safety Testing Market size was valued at USD 5.25 Billion in 2023 and is poised to grow from USD 5.86 Billion in 2024 to USD 14.21 Billion by 2032, growing at a CAGR of 11.70% during the forecast period (2025-2032).
Biological safety testing comprises a comprehensive array of meticulous procedures essential for ensuring the safety of products derived from biological sources, notably biopharmaceuticals and medical devices. Its fundamental aim revolves around assessing and mitigating potential risks associated with these products, meticulously analysing aspects such as contamination and adverse biological effects. Adherence to stringent regulatory standards is pivotal, ensuring the purity, potency, and overall safety of biological materials. Techniques like sterility testing, endotoxin assessment, and cell-based assays assume critical roles in rigorously evaluating these products, affirming their compliance with exacting safety benchmarks and assuring their suitability for clinical use and public health.
Global Market Size
USD 4.70 billion
Largest Segment
Bioburden Tests
Fastest Growth
Growth Rate
11.70% CAGR
To get more reports on the above market click here to Buy The Report
The global Biologics Safety Testing market is segmented on the basis of test, application, end-use, and region. Based on Test, it is divided into Endotoxin Test, Bioburden Tests, Sterility Test, Adventitious Agent Detection Test, Others. Based on Application, it is divided into Blood & Blood-based Products, Gene Therapy, Vaccines & Therapeutics, Stem Cells, Others. Based on End-use, it is divided into Pharmaceutical and Biotechnology Companies, Contract Development and Manufacturing Companies, Research and Academia, Others. Based on region, the market is segmented into North America, Europe, Asia-Pacific, Latin America, Middle East & Africa.
Analysis by Test Type
In 2022, the realm of biological safety testing products and services witnessed the ascendancy of the endotoxin tests segment, claiming a substantial 21.96% share of the market's revenue. This commanding position stems from the escalating utilisation of these tests across various sectors, notably within drug manufacturing processes aimed at mitigating risks associated with endotoxins. A noteworthy development in this domain unfolded in August 2022 when Lonza introduced the Nebula Multimode Reader, marking a significant stride in this landscape.
Concurrently, the bioburden tests segment is poised for rapid expansion throughout the forecast period, driven by its widespread adoption in assessing bioburden thresholds across diverse biologics and medical devices. In April 2023, a significant breakthrough emerged courtesy of STEMart, a U.S.-based provider, introducing specialised bioburden and sterility testing tailored explicitly for medical devices. This pioneering offering aligns meticulously with the rigorous regulatory standards outlined in the ISO 11731 technique.
Analysis by Application
In 2022, the vaccine and therapeutics segment emerged as the dominant application within the market, capturing a substantial market share of 23.58% and poised for further growth in the forecast period. This dominance is a result of stringent guidelines focused on ensuring the safety and efficacy of vaccines, prioritising therapeutic integrity while mitigating potential risks of toxicity. An important development in January 2023 was the announcement by BioNTech SE of a significant collaboration through a Memorandum of Understanding with the UK Government. This strategic partnership aims to expedite clinical trials for mRNA personalised immunotherapies, showcasing promising advancements in patient care and treatment.
The gene therapy segment is forecasted to experience significant growth during the forecast period, primarily propelled by concerns related to potential contamination risks arising from residual DNA. The management of residual DNA is critical due to its inherent infectivity risks, necessitating stringent measures to address this concern in the final product. Concurrently, monoclonal antibodies (mAbs) assume a crucial role in the biopharmaceutical landscape, especially in the identification and characterization of critical quality attributes (CQAs). These CQAs serve as essential benchmarks, delineating specific characteristics that determine a product's safety, purity, and efficacy.
To get detailed analysis on other segments, Request For Free Sample Report
North America emerges as the leader in shaping and propelling the market dynamics, poised to sustain its influential trajectory in the forecast period. This regional dominance is attributed to various key factors, notably the robust presence of a multitude of biotechnology and pharmaceutical companies. Renowned for its status as an innovation hub, North America consistently fosters the evolution of cutting-edge technologies, driving advancements and breakthroughs within the industry.
Asia-Pacific is poised for substantial growth, projected to experience a rapid CAGR from 2023 to 2030. This anticipated surge finds its foundation in the escalating investments funnelling in from both governmental initiatives and private sectors deeply entrenched within the biopharmaceutical and pharmaceutical domains across the region. Notably, within this landscape, China emerges as a dominant force, holding the largest market share in the Biologics Safety Testing sector.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Drivers
Rising Pharmaceutical and Biotechnology Sectors
Restraints
High Cost of Biologics
Request Free Customization of this report to help us to meet your business objectives.
The Global Biologics Safety Testing Market showcases a competitive landscape characterised by a diverse mix of well-established brands, emerging players, and specialised producers. In this dynamic environment, innovation serves as a pivotal competitive edge. Leading brands dedicate significant resources to research and development endeavours, consistently introducing fresh flavours, innovative packaging formats, and health-focused variations in response to ever-evolving consumer preferences.
Top Player’s Company Profiles
Recent Developments
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
The rapid proliferation of biopharmaceutical firms and laboratories emerges as a pivotal driving force propelling the market's growth trajectory. This influx signifies not just an expanding landscape but also heralds a forthcoming surge in novel biologics' production. This anticipated wave of innovative biologics is poised to substantially bolster the demand within the biological safety testing market. The proliferation of these firms and laboratories acts as a catalyst, fostering an environment conducive to creating and developing new biological entities. Consequently, the projected escalation in biologic production is set to drive a corresponding increase in the demand for rigorous biological safety testing, aligning seamlessly with the escalating market need to ensure the safety and efficacy of these groundbreaking biopharmaceutical products.
Report Metric | Details |
---|---|
Market size value in 2022 | USD 4.70 billion |
Market size value in 2031 | USD 12.72 billion |
Growth Rate | 11.70% |
Base year | 2023 |
Forecast period | 2024-2031 |
Forecast Unit (Value) | USD Billion |
Segments covered |
|
Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
Companies covered |
|
Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
For the Biologics Safety Testing Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Biologics Safety Testing Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Biologics Safety Testing Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Biologics Safety Testing Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Report ID: SQMIG35A2786
sales@skyquestt.com
USA +1 351-333-4748